https://doi.org/10.4070/kcj.2016.0406 www.e-kcj.org angiotensin converting enzyme (ACE) inhibitors and angiotensin II type I (AT 1 ) receptor blockers (ARBs) are equally recommended for the initiation and maintenance of anti-hypertensive treatment. However, various classes of anti-hypertensive drugs have differential impacts on insulin sensitivity despite similar blood pressure reduction. Only some classes of these drugs, including ACE inhibitors and ARBs, ameliorate insulin resistance. 6) The reninangiotensin system (RAS) is involved in many atherosclerosis steps and also modulates insulin action. Angiotensin II promotes superoxide anion generation and endothelial dysfunction. Angiotensin II activates nuclear transcription factor induced by oxidative stress, mediated by AT 1 receptors. [7] [8] [9] We reported that candesartan significantly improved flow-mediated vasodilation and reduced biomarkers of oxidant stress, inflammation, and hemostasis in patients with hypertension, independent of blood pressure reduction. 10) ACE inhibitors and ARBs also significantly reduced insulin resistance, thus improved metabolic outcomes in diabetes with a further secondary benefit for CV risk.
Whether statin benefits to cardiovascular status outweigh non-cardiovascular harm in patients above a certain threshold of cardiovascular risk remains untested, especially when comparing similar levels of CV risk and lipid lowering in the absence or presence of adverse metabolic outcomes that secondarily increase CV risk. Indeed, ideal therapy would simultaneously lower LDL cholesterol to target levels while reducing instead of increasing the risk for new onset diabetes and progression of existing diabetes. Statins attenuate increases in cardiorespiratory fitness and skeletal muscle mitochondrial content when combined with exercise training in overweight or obese patients at risk for metabolic syndrome. 11) Statin use is associated with modestly lower physical activity among community-living men, even after accounting for medical history and other potential confounding factors. 12) Muscle pain, fatigue, and weakness are common adverse side effects of statin medications. Importantly, we have demonstrated that statin therapy dose-dependently caused insulin resistance and increased the risk for type 2 diabetes mellitus. 13)14) Interestingly, we observed that statin-based combination treatment with ACE inhibitors or ARBs improved metabolic outcomes and had additive and/or synergistic effects in changing blood pressure, lipid profiles, endothelial dysfunction, inflammation, and hemostasis by both separate and interrelated mechanisms [15] [16] [17] that may help explain outcomes in recent clinical trials. [18] [19] [20] [21] The HOPE-3 study examined 12705 subjects with at least one known CV risk factor, but who had not been diagnosed with CV disease (at intermediate risk). Participants were randomly assigned to one of four groups: rosuvastatin 10 mg plus a combination pill of candesartan 16 mg and hydrocholothiazide 12.5 mg daily, rosuvastatin 10 mg plus a placebo daily, a placebo plus the combination pill daily, or two placebo pills daily. Over 5.6 years of follow-up, CV death, myocardial infarction or stroke occurred in 3.5 percent of patients receiving both drugs and in 5 percent of patients receiving only placebo. The relative risk reduction in those taking both drugs was 30 percent overall, 40 percent in those with hypertension and 20 percent in those without hypertension. 21) Here, we discuss the promising treatment strategies of statins-based combination treatment with ACE inhibitors or ARBs in patients to ameliorate risk of both CV disease and diabetes mellitus simultaneously.
Effects of Statin Therapy on Insulin Resistance
Statin therapy is very important for decreasing CV morbidity and mortality especially in secondary prevention. 2)18) Unfortunately high dose potent statins cause adverse metabolic effects including worse insulin sensitivity and glucose intolerance that contribute to increased risk of new onset diabetes and progression of existing diabetes. 13)14) Pravastatin is the only statin which has beneficial metabolic actions at equal lipid lowering doses with rosuvastatin or simvastatin. 22) It is possible that lipophilic statins are taken up by the brain and fat tissue where they may cause unfavorable pleiotropic effects including secondary actions on the regulation of insulin secretion and exacerbation of insulin resistance. By contrast, the hydrophilic statin, pravastatin improved insulin sensitivity and increased circulating adiponectin levels in humans that might have beneficial metabolic effects as well as atherogenic reduction. [22] [23] [24] Pravastatin is the only statin that requires a transporter to get across the cell membrane. Even rosuvastatin which is relatively hydrophilic (but still lipophilic relative to pravastatin) does not need a transporter to cross the cell membrane.
Rosuvastatin is less hydrophilic than pravastatin. We have demonstrated rosuvastatin treatment significantly increased fasting insulin levels, decreased plasma adiponectin levels and worsened insulin sensitivity and glucose control, while pravastatin treatment had opposite beneficial effects in hypercholesterolemic patients. 22) Diabetes onset and progression related to statin use has not been shown to increase CV events because appropriately controlled outcome studies have not been performed. Nonetheless, long-term adverse effects of new-onset diabetes mellitus and accelerated diabetes progression may generate a relative increase in CV and all cause morbidity or mortality when compared with equal lipid lowering in the absence of adverse metabolic actions. 25) Indeed, a recent large-scale randomized clinical trial strongly supports this concept. When compared to placebo, rosuvastatin treatment increased the incidence of diabetes mellitus by 28% in individuals with one or more risk factors for diabetes, but reduced CV events by 39%. By contrast, in individuals with no major diabetes risk factors, rosuvastatin treatment did not cause diabetes mellitus and reduced CV events by 52%: 13% more than the former group. 26) This may just be due to the fact that it is easier to detect adverse metabolic outcomes in patients with more risk factors. Indeed, in the first large outcome study where the primary outcome for statin therapy was prospectively designated as increased risk of diabetes, there was both a significant time and dose-dependent increase in metabolic risk for all statins except pravastatin. Moreover, the average increased risk of statin therapy for diabetes was huge (46%) in a cohort of 8749 patients with the metabolic syndrome. 25) Further, the physiological mechanisms evaluated in this study supported our previous studies suggesting the major cause of statin-induced diabetes was increased insulin resistance with a minor component of reduced insulin secretion. 13)14) 22) Two clinical genomic studies clearly demonstrated that exposure to LDL cholesterol-lowering genetic variants was associated with a higher risk of type 2 diabetes despite a significant reduction in coronary artery disease risk. 27)28) Furthermore, the effects of these variants were independent and additive. 28) These data provide insights into potential adverse effects of LDL cholesterol-lowering therapy. Although, the increased risk of type 2 diabetes appeared confined to persons with impaired fasting glucose levels, it might simply have been more difficult to detect increased diabetes risk in the absence of initial metabolic abnormalities. 28) It is likely that previous large outcome studies of statin therapy underestimated the magnitude of metabolic risk because they did not have diabetes onset as a primary study outcome, and the patient population was different with fewer initial metabolic risks.
Insulin Resistance Associated with ACE Inhibitors or ARBs
Insulin resistance plays a pivotal role in hypertension, hypercholesterolemia, and atherosclerosis. About half of hypertensive individuals are hyperinsulinemic with insulin resistance, and up to three fourths of people with type 2 diabetes have hypertension. The prevalence of dyslipidemia is more than double in hypertensive patients when compared with a normotensive population. 8) When compared with other anti-hypertensive drugs, ACE inhibitors and ARBs improved insulin sensitivity in hypertensive patients. 7) RAS also has multiple effects in the central nervous system, skeletal muscle, liver, and adipose tissue that may interfere with insulin action. Thus, RAS dysregulation may contribute to the evolution of insulin resistance. Conversely, RAS blockade may potentially help prevent new-onset diabetes. Indeed, RAS blockade directly augmented insulin-stimulated glucose uptake, promoted adipogenesis, and induced peroxisome proliferator-activated receptor-γ activity that promoted adipocyte differentiation. 10) ACE inhibitors and ARBs are associated with reductions in the incidence of new-onset diabetes independent of blood pressure reduction. 29) Another important benefit of RAS inhibitors is that they may attenuate vascular complications associated with insulin resistance. 30) In the milieu of insulin resistance, the CV system is sensitized to adverse RAS tropic effects, evidenced by the frequent occurrence of diffuse vascular disease and left ventricular hypertrophy in diabetic patients, even when lipid and blood pressure levels are normal. High insulin levels stimulate AT 1 receptors, which activate RAS and also activate the cardiac sympathetic nervous system. 10) Accordingly, ACE inhibitors and ARBs reverse endothelial dysfunction and reduce oxidant stress and inflammatory cytokines, suggesting that ACE inhibitors and ARBs have anti-atherogenic effects in hypertensive patients that contribute to reduction of insulin resistance.
Statin-Based Combined Treatment with ACE Inhibitors or ARBs to Maximize Cardiovascular Protection
Endothelial dysfunction and insulin resistance play crucial roles in the pathogenesis of atherosclerosis. Importantly, elevated levels of free fatty acids associated with insulin resistance, obesity, diabetes mellitus, and the metabolic syndrome cause endothelial dysfunction by activating innate immune inflammatory pathways upstream of NF-κB. Thus, inflammation and oxidative stress contribute to endothelial dysfunction and insulin resistance while endothelial dysfunction and insulin resistance promote oxidative stress and inflammation. [8] [9] [10] Of note, experimental and clinical studies demonstrate crosstalk between hypercholesterolemia and RAS at multiple levels. Hypercholesterolemic rabbits display enhanced vascular expression of AT 1 receptors that mediate increased angiotensin II activity, thus increasing blood pressure. 31) Statins reverse the blood pressure elevating response to angiotensin II infusion by decreasing AT 1 receptor density. 32) Therefore, statins and ACE inhibitors or ARBs may have the potential to exert additive/synergistic beneficial effects on both endothelial function and insulin sensitivity when compared to monotherapy in patients with cardiovascular risk factors affected by both separate and interrelated mechanisms (Fig. 1) . [8] [9] [10] We reported additive beneficial vascular effects of statin and ACE inhibitors or ARB combined therapy when compared https://doi.org/10.4070/kcj.2016.0406 www.e-kcj.org with monotherapy alone. 15)16) Combination therapy also showed a metabolic benefit due to ACE inhibitors or ARBs therapy. Recently, we observed that pravastatin combined with valsartan therapy had additive beneficial effects on endothelial dysfunction and simultaneously had additive beneficial effects that increased plasma adiponectin, lowered fasting insulin levels, and improved insulin sensitivity when compared with monotherapy alone in a hypertensive population (Fig. 2) . 17) Indeed, large-scale clinical studies assessed the 'synergy' of statins and ACE inhibitors in reducing vascular events in patients with coronary heart disease during a 3-year follow-up. The statin and ACE inhibitor combination reduced CV events more than statin monotherapy and considerably more than ACE inhibitor monotherapy. 19) This benefit may be related to combined beneficial effects on endothelial function, vascular inflammation and the initiation, progression and rupture of atheromatous plaques. 20) The HOPE-3 trial, designed to focus on preventing CV disease before it starts, was the first to assess outcomes of preventative combination treatment with statin and ARB drugs in a large, globally diverse population at intermediate risk for developing CV disease. 21) Clinical Implication 33) Further, various strategies to reduce residual CV disease risk in hypertensive patients using different classes of anti-hypertensive medications reduced CV disease risk by only 20 to 25%. 1) However, controlling hypercholesterolemia in hypertensive patients with statins reduced residual CV disease risk by 35 to 40%. 2) These data suggest that effective combined treatment of both hypertension and hypercholesterolemia reduced CV disease risk by ≥50%. Thus, statins are paramount of importance for reducing CV disease risk. 2) Unfortunately, most hypertension guidelines currently focus on which single agents to use and what blood pressure to aim for without emphasizing the potential benefits of combination treatment in patients with hypertension.
There is strong scientific evidence obtained from experimental and clinical studies that supports combined statin and ACE inhibitor or ARB therapy to optimize CV protection in high risk patients while minimizing metabolic risk. Hypercholesterolemia and hypertension share common pathophysiologies such as endothelial dysfunction and insulin resistance, and both are common risk Angiotensin II binds to AT 1 R resulting in enzymatic production of oxygen-derived free radicals. FFA also promote oxygenderived free radical generation in vascular endothelial cells and smooth muscle cells. This leads to dissociation of inhibitory factor with subsequent activation of NF-κB which stimulates expression of proinflammatory genes, chemokines, and cytokines. Importantly, elevated levels of FFA associated with insulin resistance, obesity, diabetes mellitus, and the metabolic syndrome cause endothelial dysfunction by activating innate immune inflammatory pathways upstream of NF-κB. Thus, inflammation and oxidative stress contribute to endothelial dysfunction and insulin resistance while endothelial dysfunction and insulin resistance promote oxidative stress and inflammation. These have shown the reciprocal relationships between insulin resistance and endothelial dysfunction. Statins down-regulate the expression of AT 1 R via reducing lowering low-density lipoprotein-cholesterol levels. KLF2 is implicated as a key molecule maintaining endothelial function. High glucose-induced, FOXO1-mediated KLF2 suppression was reversed by statin treatment. Further, experimental studies have shown a cross-talk between hypercholesterolemia and RAS at multiple steps. Accordingly, combined therapy with statins and RAS inhibitors show additive/synergistic beneficial effects on endothelial dysfunction and insulin resistance when compared with monotherapy in patients with cardiovascular risk factors by both distinct and interrelated mechanisms. Reproduced with permission from Koh et al. 8)9)35-37) ACEI: angiotensin-converting enzyme inhibitor, ARB: angiotensin-receptor blocker, FFA: free fatty acids, MCP: monocyte chemotactic protein, TNF: tumor necrosis factor, ICAM: intercellular adhesion molecule, PAI: plasminogen activator inhibitor, CRP: C-reactive protein, AT 1 R: angiotensin II type I receptor, IKKB: inhibitor of nuclear factor kappa B kinase subunit, NADH/NADPH: nicotinamide dehydrogenase/nicotinamide diphosphate dehydrogenase, FOXO1: forkhead box protein O1, Rac1: Ras-related C3 botulinum toxin substrate 1, KLF2: Krüppel-like factor 2, RAS: renin-angiotensin system, NF-κB: nuclear transcription factor, eNOS: endothelial nitric oxide synthase. ARBs is a promising approach to maximize therapeutic benefit while reducing inherent metabolic risks of potent statins. Now we propose a simple but practical recommendation regarding combining potent statin therapy with other drugs to optimize simultaneous CV and metabolic benefits while minimizing adverse events. For patients with acute coronary syndrome, high doses of potent statins such as atorvastatin or rosuvastatin +/-ezetimibe are recommended because the impact of CV events is likely to be greater than additional diabetogenic or other risks. If patients stabilize after 3 months or in patients with stable angina, optimal doses of statins +/-ezetimibe combined with RAS blockades or peroxisome proliferator-activated receptor α agonists are recommended. For the primary prevention of heart disease, if patients do not have risk factors for diabetes such as impaired glucose tolerance, obesity, or metabolic syndrome, we recommend low (for Asian) or optimal (for Caucasian) dose statins alone; if patients do not have risk factors for diabetes we recommend statins with beneficial metabolic actions such as pravastatin. However, if patients have risk factors for diabetes, we recommend low or optimal dose statins +/-ezetimibe combined with RAS blockades or peroxisome proliferator-activated receptor α agonists to reduce the diabetogenic effect of statins. These treatment guidelines might provide the beneficial effects of lowering LDL cholesterol while minimizing adverse outcomes from high-dose statin administration for CV disease amelioration (Table 1) . [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] 
